What is TEVA PHARM INDUS LTD's earnings per share (EPS)?

TEVA PHARM INDUS LTD (TEVJF) reported diluted earnings per share of $1.21 for fiscal year 2025. This represents a 183.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

TEVA PHARM INDUS LTD (TEVJF) Financials

TEVJF

FY2025 annual

Revenue $17.3B +4.3% YoY

Net Income $1.4B +186.0% YoY

EPS (Diluted) $1.21 +183.4% YoY

Free Cash Flow $1.1B +53.3% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 29, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TEVJF SEC filings page.

TEVA PHARM INDUS LTD (TEVJF) reported $17.3B in revenue for fiscal year 2025, up 4.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TEVJF FY2025 2026-08-29

Teva’s dominant mechanic is a 2025 earnings rebound that restored margins and cash generation while leaving an intangible-heavy balance sheet.

The 2025 rebound is stronger than the income statement alone suggests: operating margin moved from -1.8% in FY2024 to 12.5% in FY2025, reversing the prior year’s operating loss. Net income of $1.41B was accompanied by operating cash flow of $1.65B, while positive free cash flow remained after $501M of capital expenditures, indicating that reported profitability translated into cash rather than existing only through accounting items.

Debt-to-equity fell from 6.3x in FY2024 to 4.2x in FY2025, showing that the recovery improved the balance-sheet relationship between obligations and shareholder capital. Total liabilities declined to $32.8B while equity recovered to $7.9B, though the structure remains heavily financed by liabilities.

Gross margin widened 3.1 percentage points while revenue growth was 4.3%, so the profit improvement was not simply a volume effect and likely reflects mix or cost changes. Goodwill of $16.0B remains about 2.0x equity, making the asset base materially dependent on intangible values.

Financial Health Signals

Financial health score not available

TEVA PHARM INDUS LTD does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

0.74

TEVA PHARM INDUS LTD scores 0.74, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($33.1B) relative to total liabilities ($32.8B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

7/8

TEVA PHARM INDUS LTD passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.17x

For every $1 of reported earnings, TEVA PHARM INDUS LTD generates $1.17 in operating cash flow ($1.6B OCF vs $1.4B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Adequate

2.35x

TEVA PHARM INDUS LTD earns $2.35 in operating income for every $1 of interest expense ($2.2B vs $916.0M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.1B

YoY-0.8%

QoQ+4.0%

5Y CAGR+1.2%

10Y CAGR-1.9%

TEVA PHARM INDUS LTD generated $4.1B in revenue in Q2 2026. This represents a decrease of 0.8% from the same quarter a year earlier. Against the prior quarter it is up 4.0%.

EBITDA

$10.0M

YoY-98.6%

QoQ-98.9%

TEVA PHARM INDUS LTD's EBITDA was $10.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 98.6% from the same quarter a year earlier. Against the prior quarter it is down 98.9%.

Net Income

-$576.0M

YoY-304.3%

QoQ-256.1%

TEVA PHARM INDUS LTD reported -$576.0M in net income in Q2 2026. This represents a decrease of 304.3% from the same quarter a year earlier. Against the prior quarter it is down 256.1%.

EPS (Diluted)

-$0.49

YoY-304.2%

QoQ-258.1%

TEVA PHARM INDUS LTD earned -$0.49 per diluted share (EPS) in Q2 2026. This represents a decrease of 304.2% from the same quarter a year earlier. Against the prior quarter it is down 258.1%.

Cash & Balance Sheet

Free Cash Flow

$307.0M

YoY+134.4%

QoQ+247.6%

5Y CAGR+23.9%

10Y CAGR-9.0%

TEVA PHARM INDUS LTD generated $307.0M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 134.4% from the same quarter a year earlier. Against the prior quarter it is up 247.6%.

Cash & Debt

$3.7B

YoY+69.1%

QoQ-2.3%

5Y CAGR+8.5%

10Y CAGR-6.3%

TEVA PHARM INDUS LTD held $3.7B in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

1.17B

YoY+1.6%

QoQ+0.1%

5Y CAGR+1.1%

10Y CAGR+102.2%

TEVA PHARM INDUS LTD had 1.17B shares outstanding in Q2 2026. This represents an increase of 1.6% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

52.0%

YoY+1.6pp

QoQ+2.5pp

TEVA PHARM INDUS LTD's gross margin was 52.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 1.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.5 percentage points.

Operating Margin

-5.6%

YoY-16.5pp

QoQ-22.0pp

TEVA PHARM INDUS LTD's operating margin was -5.6% in Q2 2026, reflecting core business profitability. This is down 16.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 22.0 percentage points.

Net Margin

-13.9%

YoY-20.7pp

QoQ-23.2pp

TEVA PHARM INDUS LTD's net profit margin was -13.9% in Q2 2026, showing the share of revenue converted to profit. This is down 20.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 23.2 percentage points.

Return on Equity

-7.4%

YoY-11.6pp

QoQ-11.9pp

TEVA PHARM INDUS LTD's ROE was -7.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 11.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 11.9 percentage points.

Capital Allocation

R&D Spending

$970.0M

YoY+297.5%

QoQ+336.9%

TEVA PHARM INDUS LTD invested $970.0M in research and development in Q2 2026. This represents an increase of 297.5% from the same quarter a year earlier. Against the prior quarter it is up 336.9%.

Capital Expenditures

$104.0M

YoY+8.3%

QoQ-38.1%

5Y CAGR-1.6%

10Y CAGR-5.1%

TEVA PHARM INDUS LTD invested $104.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 8.3% from the same quarter a year earlier. Against the prior quarter it is down 38.1%.

Share Buybacks

Not reported for Q2 2026.

TEVJF Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TEVJF quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$14.1B	$17.3B+4.3%	$16.5B+4.4%	$15.8B+6.2%	$14.9B-6.0%	$15.9B-4.7%	$16.7B-1.4%	$16.9B-7.6%	$18.3B-16.4%	$21.9B-0.2%	$21.9B+11.5%	$19.7B-3.1%	$20.3B-0.2%	$20.3B0.0%	$20.3B+10.9%	$18.3B
Cost of Revenue	N/A	$8.3B-1.9%	$8.5B+3.4%	$8.2B+3.1%	$8.0B-4.0%	$8.3B-7.3%	$8.9B-4.5%	$9.4B-6.3%	$10.0B-11.2%	$11.2B+11.9%	$10.0B+21.1%	$8.3B-10.0%	$9.2B-4.1%	$9.6B-0.6%	$9.7B+9.9%	$8.8B
Gross Profit	N/A	$8.9B+10.8%	$8.1B+5.5%	$7.6B+9.6%	$7.0B-8.2%	$7.6B-1.7%	$7.7B+2.5%	$7.5B-9.1%	$8.3B-21.8%	$10.6B-10.5%	$11.9B+4.4%	$11.4B+2.7%	$11.1B+3.3%	$10.7B+0.5%	$10.7B+11.9%	$9.5B
R&D Expenses	N/A	$1.0B+1.5%	$998.0M+4.7%	$953.0M+872.4%	$98.0M-89.9%	$967.0M-3.0%	$997.0M-1.3%	$1.0B+786.0%	$114.0M-34.9%	$175.0M-58.5%	$422.0M+1105.7%	$35.0M	$0-100.0%	$5.0M-93.2%	$73.0M+386.7%	$15.0M
SG&A Expenses	N/A	$1.3B+10.9%	$1.2B-0.1%	$1.2B-1.5%	$1.2B+7.4%	$1.1B-6.3%	$1.2B-1.6%	$1.2B-8.2%	$1.3B-10.5%	$1.5B+12.9%	$1.3B-5.5%	$1.4B+11.8%	$1.2B-1.8%	$1.2B+0.1%	$1.2B+32.8%	$932.0M
Operating Income	N/A	$2.2B+811.9%	-$303.0M-170.0%	$433.0M+119.7%	-$2.2B-228.0%	$1.7B+148.0%	-$3.6B-706.3%	-$443.0M+72.9%	-$1.6B+90.6%	-$17.5B-911.7%	$2.2B-35.7%	$3.4B-15.2%	$4.0B+139.6%	$1.6B-25.2%	$2.2B-29.1%	$3.1B
EBITDA	N/A	$3.2B+317.9%	$756.0M-52.3%	$1.6B+278.4%	-$889.0M-129.2%	$3.0B+251.2%	-$2.0B-257.5%	$1.3B+523.9%	$205.0M+101.3%	-$15.4B-517.9%	$3.7B-21.1%	$4.7B-14.6%	$5.5B+65.9%	$3.3B-15.9%	$3.9B-6.3%	$4.2B
Interest Expense	N/A	$916.0M-8.6%	$1.0B-2.6%	$1.0B+10.6%	$930.0M+4.4%	$891.0M-1.1%	$901.0M+9.6%	$822.0M-10.7%	$920.0M+5.1%	$875.0M+60.3%	$546.0M+102.2%	$270.0M-10.0%	$300.0M-4.5%	$314.0M-11.5%	$355.0M+51.7%	$234.0M
Income Tax	N/A	-$180.0M-126.6%	$676.0M+9757.1%	-$7.0M+98.9%	-$643.0M-404.7%	$211.0M+225.6%	-$168.0M+39.6%	-$278.0M-42.6%	-$195.0M+89.9%	-$1.9B-471.0%	$521.0M-17.8%	$634.0M+7.3%	$591.0M+1474.4%	-$43.0M+68.6%	-$137.0M-207.9%	$127.0M
Net Income	N/A	$1.4B+186.0%	-$1.6B-193.2%	-$559.0M+77.1%	-$2.4B-686.6%	$417.0M+110.5%	-$4.0B-299.4%	-$999.0M+53.5%	-$2.1B+86.8%	-$16.3B-5043.8%	$329.0M-79.3%	$1.6B-48.0%	$3.1B+140.7%	$1.3B-35.4%	$2.0B-28.9%	$2.8B
EPS (Basic)	N/A	$1.23+184.8%	-$1.45-190.0%	-$0.50+77.3%	-$2.20-678.9%	$0.38+110.4%	-$3.64-300.0%	-$0.91+61.3%	-$2.35+85.5%	-$16.26-23328.6%	$0.07-96.2%	$1.84-48.6%	$3.58+140.3%	$1.49-33.8%	$2.25-27.4%	$3.10
EPS (Diluted)	$0.60	$1.21+183.4%	-$1.45-190.0%	-$0.50+77.3%	-$2.20-678.9%	$0.38+110.4%	-$3.64-300.0%	-$0.91+61.3%	-$2.35+85.5%	-$16.26	$0.07	$1.82-48.9%	$3.56+138.9%	$1.49-33.8%	$2.25-27.2%	$3.09
Diluted Shares (Avg)	N/A	1.16B+2.8%	1.13B+1.1%	1.12B+0.8%	1.11B+0.3%	1.11B+1.1%	1.09B+0.4%	1.09B+6.9%	1.02B+0.5%	1.02B	961M	864M+0.7%	858M+0.9%	850M-2.6%	873M-2.2%	893M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$4.1B-0.8%	$4.0B+2.3%	$1.5B-64.5%	$4.5B+3.4%	$4.2B+0.3%	$3.9B+1.9%	$4.2B-5.1%	$4.3B+12.5%
Cost of Revenue	$2.0B-4.1%	$2.0B-0.1%	N/A	$2.2B-0.3%	$2.1B-3.1%	$2.0B-1.7%	$2.1B+3.4%	$2.2B+9.2%
Gross Profit	$2.2B+2.4%	$2.0B+5.1%	N/A	$2.3B+7.3%	$2.1B+3.9%	$1.9B+6.0%	$2.1B-12.2%	$2.1B+16.0%
R&D Expenses	$970.0M+297.5%	$222.0M-10.1%	N/A	$256.0M+6.7%	$244.0M-9.3%	$247.0M+2.1%	$247.0M+9.3%	$240.0M-5.1%
SG&A Expenses	$317.0M+3.9%	$304.0M+2.4%	N/A	$317.0M+6.4%	$305.0M+7.8%	$297.0M+6.8%	$302.0M+3.8%	$298.0M+11.2%
Operating Income	-$231.0M-150.8%	$652.0M+25.6%	N/A	$882.0M+1829.4%	$455.0M+9200.0%	$519.0M+338.1%	-$29.0M-103.8%	-$51.0M-114.8%
EBITDA	$10.0M-98.6%	$891.0M+16.8%	N/A	$1.1B+443.8%	$706.0M+178.0%	$763.0M+1313.0%	$240.0M-76.5%	$208.0M-66.8%
Income Tax	$121.0M+255.1%	$67.0M-9.5%	N/A	$214.0M+210.1%	-$78.0M-112.4%	$74.0M+242.3%	$29.0M-27.5%	$69.0M+675.0%
Net Income	-$576.0M-304.3%	$369.0M+72.4%	N/A	$433.0M+199.1%	$282.0M+133.3%	$214.0M+254.0%	-$217.0M-146.8%	-$437.0M-733.3%
EPS (Basic)	-$0.49-296.0%	$0.32+68.4%	$0.42+321.1%	$0.38+197.4%	$0.25+133.3%	$0.19+258.3%	-$0.19-146.3%	-$0.39-750.0%
EPS (Diluted)	-$0.49-304.2%	$0.31+72.2%	$0.41+315.8%	$0.37+194.9%	$0.24+132.0%	$0.18+250.0%	-$0.19-146.3%	-$0.39-750.0%
Diluted Shares (Avg)	1.17B+0.3%	1.18B+1.7%	N/A	1.16B+2.7%	1.16B+2.5%	1.16B+3.2%	N/A	1.13B-0.2%

Not reported in any period shown, so not listed: Interest Expense.

TEVJF Balance Sheet

TEVJF quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$40.7B+3.6%	$39.3B-9.6%	$43.5B-1.2%	$44.0B-7.7%	$47.7B-5.9%	$50.6B-11.9%	$57.5B-5.3%	$60.7B-14.1%	$70.6B-24.1%	$93.1B+71.6%	$54.2B+16.8%	$46.4B-2.3%	$47.5B-6.1%	$50.6B+0.9%	$50.1B
Current Assets	$13.9B+11.1%	$12.6B+0.5%	$12.5B+3.6%	$12.1B-4.2%	$12.6B-3.3%	$13.0B-3.4%	$13.5B-2.4%	$13.8B-10.3%	$15.4B-10.7%	$17.2B-6.4%	$18.4B+27.8%	$14.4B+4.9%	$13.7B-16.1%	$16.4B+13.2%	$14.5B
Cash & Equivalents	$3.6B+7.8%	$3.3B+2.3%	$3.2B+15.2%	$2.8B+29.4%	$2.2B-0.6%	$2.2B+10.2%	$2.0B+10.8%	$1.8B+85.0%	$963.0M-2.5%	$988.0M-85.8%	$6.9B+212.0%	$2.2B+114.5%	$1.0B-63.9%	$2.9B+162.7%	$1.1B
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$3.2B+5.7%	$3.0B-25.2%	$4.0B+4.9%	$3.8B+0.4%	$3.8B-13.3%	$4.4B-0.4%	$4.4B-6.5%	$4.7B-3.9%	$4.9B-0.6%	$5.0B+24.9%	$4.0B-9.3%	$4.4B-13.5%	$5.1B-8.2%	$5.5B+9.8%	$5.0B
Accounts Receivable	$3.7B+21.2%	$3.1B-10.2%	$3.4B-7.8%	$3.7B-18.4%	$4.5B-1.1%	$4.6B-19.3%	$5.7B-2.5%	$5.8B-18.3%	$7.1B-5.3%	$7.5B+40.6%	$5.3B-1.1%	$5.4B+1.3%	$5.3B-4.2%	$5.6B-10.3%	$6.2B
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$16.0B0.0%	$16.0B-6.9%	$17.2B0.0%	$17.2B-2.6%	$17.6B-14.5%	$20.6B-17.0%	$24.8B-0.3%	$24.9B-12.3%	$28.4B-36.0%	$44.4B+133.4%	$19.0B+3.4%	$18.4B-3.0%	$19.0B+0.7%	$18.9B+3.1%	$18.3B
Total Liabilities	$32.8B-2.3%	$33.6B-4.9%	$35.4B-0.2%	$35.4B-2.8%	$36.4B-8.0%	$39.6B-6.7%	$42.4B-5.5%	$44.9B-13.5%	$51.9B-10.7%	$58.1B+138.9%	$24.3B+5.4%	$23.1B-7.3%	$24.9B-10.3%	$27.7B-0.2%	$27.8B
Current Liabilities	$13.5B+5.2%	$12.8B+4.5%	$12.2B+6.8%	$11.5B+4.0%	$11.0B-16.2%	$13.2B-3.7%	$13.7B-4.5%	$14.3B-20.1%	$17.9B-3.1%	$18.5B+42.2%	$13.0B+5.8%	$12.3B+2.7%	$12.0B-7.2%	$12.9B-5.8%	$13.7B
Non-Current Liabilities	$19.4B-6.9%	$20.8B-9.9%	$23.1B-3.5%	$23.9B-5.7%	$25.4B-3.9%	$26.4B-8.1%	$28.7B-6.0%	$30.6B-10.0%	$33.9B-14.2%	$39.6B+250.2%	$11.3B+4.9%	$10.8B-16.5%	$12.9B-13.1%	$14.9B+5.2%	$14.1B
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$28.8B-11.4%	$32.5B+289.1%	$8.4B-2.4%	$8.6B-23.5%	$11.2B-20.8%	$14.1B+24.1%	$11.4B
Total Equity	$7.9B+47.2%	$5.4B-28.4%	$7.5B-3.8%	$7.8B-24.1%	$10.3B+2.5%	$10.0B-28.2%	$14.0B-5.0%	$14.7B-15.3%	$17.4B-47.9%	$33.3B+12.0%	$29.8B+27.7%	$23.3B+3.3%	$22.6B-0.9%	$22.8B+2.6%	$22.2B
Retained Earnings	-$13.8B+9.3%	-$15.2B-12.1%	-$13.5B-4.3%	-$13.0B-23.2%	-$10.5B+3.8%	-$10.9B-57.4%	-$7.0B-16.8%	-$6.0B-56.7%	-$3.8B-127.9%	$13.6B-8.4%	$14.9B+2.9%	$14.4B+15.2%	$12.5B+1.5%	$12.3B+9.4%	$11.3B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$39.9B-0.7%	$40.0B+4.2%	$40.7B+3.6%	$39.9B-4.6%	$40.1B-2.9%	$38.4B-10.2%	$39.3B-9.6%	$41.8B-0.8%
Current Assets	$13.8B+9.0%	$13.7B+18.9%	$13.9B+11.1%	$12.7B+3.4%	$12.6B+8.5%	$11.5B-6.3%	$12.6B+0.5%	$12.3B+7.8%
Cash & Equivalents	$3.7B+69.1%	$3.7B+120.4%	$3.6B+7.8%	$2.2B-33.6%	$2.2B-4.3%	$1.7B-43.3%	$3.3B+2.3%	$3.3B+47.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$3.2B-7.9%	$3.2B-2.2%	$3.2B+5.7%	$3.3B-16.1%	$3.5B-10.9%	$3.2B-17.8%	$3.0B-25.2%	$4.0B-2.3%
Accounts Receivable	$3.5B-2.0%	$3.4B+0.3%	$3.7B+21.2%	$3.8B+10.1%	$3.6B-5.4%	$3.4B-2.1%	$3.1B-10.2%	$3.5B+2.3%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$15.8B-0.7%	$15.8B+2.2%	$16.0B0.0%	$15.9B-1.1%	$15.9B-3.3%	$15.5B-9.0%	$16.0B-6.9%	$16.1B-4.5%
Total Liabilities	$32.1B-3.6%	$31.8B-1.0%	$32.8B-2.3%	$32.6B-7.8%	$33.3B-4.2%	$32.1B-8.8%	$33.6B-4.9%	$35.4B+1.9%
Current Liabilities	$15.6B+31.9%	$13.5B+21.3%	$13.5B+5.2%	$11.5B-16.7%	$11.9B-9.0%	$11.2B-19.1%	$12.8B+4.5%	$13.8B+21.1%
Non-Current Liabilities	$16.5B-23.2%	$18.3B-12.9%	$19.4B-6.9%	$21.1B-2.2%	$21.4B-1.4%	$21.0B-2.1%	$20.8B-9.9%	$21.6B-7.4%
Total Equity	$7.8B+13.6%	$8.2B+31.4%	$7.9B+47.2%	$7.3B+19.5%	$6.8B+7.4%	$6.3B-14.0%	$5.4B-28.4%	$6.1B-12.5%
Retained Earnings	-$14.0B+4.8%	-$13.4B+10.5%	-$13.8B+9.3%	-$14.2B+4.8%	-$14.7B-1.1%	-$15.0B-9.4%	-$15.2B-12.1%	-$15.0B-6.9%

Not reported in any period shown, so not listed: Long-Term Debt.

TEVJF Cash Flow Statement

TEVJF quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$1.9B	$1.6B+32.2%	$1.2B-8.8%	$1.4B-14.0%	$1.6B+99.2%	$798.0M-34.4%	$1.2B+62.6%	$748.0M-69.4%	$2.4B+9.9%	$2.2B-57.4%	$5.2B-5.7%	$5.5B+8.1%	$5.1B+58.4%	$3.2B-29.2%	$4.6B+10.6%	$4.1B
Depreciation & Amortization	N/A	$1.0B-5.4%	$1.1B-8.2%	$1.2B-11.9%	$1.3B-1.7%	$1.3B-14.6%	$1.6B-9.6%	$1.7B-6.5%	$1.8B-12.8%	$2.1B+38.6%	$1.5B+16.5%	$1.3B-13.3%	$1.5B-8.2%	$1.6B-3.9%	$1.7B+59.8%	$1.1B
Stock-Based Compensation	N/A	$157.0M+27.6%	$123.0M+1.7%	$121.0M-2.4%	$124.0M+4.2%	$119.0M-7.8%	$129.0M+8.4%	$119.0M-23.2%	$155.0M+16.5%	$133.0M+7.3%	$124.0M+6.0%	$117.0M+23.2%	$95.0M+48.4%	$64.0M-22.0%	$82.0M-9.9%	$91.0M
Capital Expenditures	$550.0M	$501.0M+0.6%	$498.0M-5.3%	$526.0M-4.0%	$548.0M-2.5%	$562.0M-2.8%	$578.0M+10.1%	$525.0M-19.4%	$651.0M-25.5%	$874.0M-3.0%	$901.0M+16.7%	$772.0M-16.9%	$929.0M-9.9%	$1.0B-6.6%	$1.1B+4.8%	$1.1B
Free Cash Flow	$1.3B	$1.1B+53.3%	$749.0M-11.0%	$842.0M-19.2%	$1.0B+341.5%	$236.0M-63.0%	$638.0M+186.1%	$223.0M-87.6%	$1.8B+32.9%	$1.4B-68.8%	$4.3B-9.4%	$4.8B+13.6%	$4.2B+90.3%	$2.2B-36.4%	$3.5B+12.6%	$3.1B
Investing Cash Flow	$38.0M	$737.0M-6.9%	$792.0M-18.2%	$968.0M+47.6%	$656.0M-56.9%	$1.5B+76.5%	$863.0M-36.3%	$1.4B-27.4%	$1.9B-45.9%	$3.4B+109.6%	-$35.7B-542.2%	-$5.6B-283.8%	-$1.4B-26.4%	-$1.1B-1.1%	-$1.1B+85.1%	-$7.6B
Financing Cash Flow	-$401.0M	-$2.2B-20.1%	-$1.8B+6.4%	-$1.9B-28.6%	-$1.5B+31.5%	-$2.2B-15.2%	-$1.9B+2.1%	-$1.9B+42.5%	-$3.4B+41.7%	-$5.8B-122.8%	$25.2B+424.8%	$4.8B+302.3%	-$2.4B+38.8%	-$3.9B-131.4%	-$1.7B-150.3%	$3.3B
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$12.0M-98.7%	$901.0M-30.9%	$1.3B+12.8%	$1.2B-0.1%	$1.2B+6.2%	$1.1B+27.4%	$855.0M+6.9%	$800.0M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$439.0M-12.2%	$500.0M+0.6%	$497.0M-57.2%	$1.2B+29.1%	$899.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$411.0M+81.1%	-$40.0M+61.9%	$1.2B+101.4%	$369.0M-46.8%	$227.0M+120.4%	-$105.0M+15.3%	$575.0M-51.4%	$693.0M+13760.0%
Depreciation & Amortization	$241.0M-4.0%	$239.0M-2.0%	$260.0M-3.3%	$249.0M-3.9%	$251.0M-3.1%	$244.0M-10.3%	$269.0M+1.1%	$259.0M-8.5%
Stock-Based Compensation	$40.0M+5.3%	$43.0M+26.5%	N/A	$34.0M+17.2%	$38.0M+18.8%	$34.0M+21.4%	N/A	$29.0M-6.5%
Capital Expenditures	$104.0M+8.3%	$168.0M+32.3%	$142.0M+10.1%	$136.0M-8.1%	$96.0M-1.0%	$127.0M+2.4%	$129.0M+8.4%	$148.0M-0.7%
Free Cash Flow	$307.0M+134.4%	-$208.0M+10.3%	$1.0B+127.8%	$233.0M-57.2%	$131.0M+2083.3%	-$232.0M+6.5%	$446.0M-58.1%	$545.0M+478.5%
Investing Cash Flow	-$491.0M-308.1%	$229.0M+13.9%	$165.0M-18.3%	$135.0M-49.6%	$236.0M+32.6%	$201.0M+39.6%	$202.0M-32.9%	$268.0M+45.7%
Financing Cash Flow	-$1.0M-116.7%	$13.0M+100.7%	$40.0M+105.9%	-$453.0M	$6.0M+100.6%	-$1.7B-1055.0%	-$674.0M-17.0%	$0+100.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

TEVJF Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TEVJF quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	51.8%+3.1pp	48.7%+0.5pp	48.3%+1.5pp	46.7%-1.1pp	47.8%+1.5pp	46.4%+1.8pp	44.6%-0.8pp	45.4%-3.2pp	48.6%-5.6pp	54.1%-3.6pp	57.8%+3.2pp	54.5%+1.8pp	52.7%+0.3pp	52.4%+0.5pp	52.0%
Operating Margin	12.5%+14.3pp	-1.8%-4.6pp	2.7%+17.4pp	-14.7%-25.5pp	10.8%+32.3pp	-21.4%-18.8pp	-2.6%+6.3pp	-9.0%+71.0pp	-80.0%-89.8pp	9.8%-7.2pp	17.1%-2.4pp	19.5%+11.4pp	8.1%-2.7pp	10.8%-6.1pp	17.0%
Net Margin	8.2%+18.1pp	-9.9%-6.4pp	-3.5%+12.9pp	-16.4%-19.0pp	2.6%+26.6pp	-23.9%-18.0pp	-5.9%+5.8pp	-11.8%+62.7pp	-74.4%-75.9pp	1.5%-6.6pp	8.1%-7.0pp	15.1%+8.8pp	6.3%-3.4pp	9.7%-5.4pp	15.1%
Return on Equity	17.8%+48.3pp	-30.5%-23.0pp	-7.4%+23.9pp	-31.3%-35.4pp	4.1%+43.9pp	-39.8%-32.6pp	-7.1%+7.5pp	-14.6%+79.1pp	-93.7%-94.7pp	1.0%-4.3pp	5.3%-7.8pp	13.1%+7.5pp	5.6%-3.0pp	8.6%-3.8pp	12.4%
Return on Assets	3.5%+7.6pp	-4.2%-2.9pp	-1.3%+4.3pp	-5.6%-6.4pp	0.9%+8.8pp	-7.9%-6.1pp	-1.7%+1.8pp	-3.5%+19.5pp	-23.0%-23.4pp	0.4%-2.6pp	2.9%-3.6pp	6.6%+3.9pp	2.7%-1.2pp	3.9%-1.6pp	5.5%
Current Ratio	1.04+0.1x	0.980.0x	1.020.0x	1.05-0.1x	1.14+0.2x	0.990.0x	0.980.0x	0.96+0.1x	0.86-0.1x	0.93-0.5x	1.41+0.2x	1.170.0x	1.15-0.1x	1.27+0.2x	1.06
Debt-to-Equity	4.15-2.1x	6.25+1.5x	4.71+0.2x	4.54+1.0x	3.54-0.4x	3.95+0.9x	3.040.0x	3.05+1.4x	1.66+0.7x	0.98+0.7x	0.28-0.1x	0.37-0.1x	0.50-0.1x	0.62+0.1x	0.51
Asset Turnover	0.420.0x	0.42+0.1x	0.360.0x	0.340.0x	0.330.0x	0.330.0x	0.290.0x	0.300.0x	0.31+0.1x	0.24-0.1x	0.36-0.1x	0.440.0x	0.430.0x	0.400.0x	0.37
FCF Margin	6.7%+2.1pp	4.5%-0.8pp	5.3%-1.7pp	7.0%+5.5pp	1.5%-2.3pp	3.8%+2.5pp	1.3%-8.5pp	9.8%+3.6pp	6.2%-13.6pp	19.7%-4.5pp	24.3%+3.6pp	20.7%+9.8pp	10.9%-6.2pp	17.1%+0.2pp	16.8%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	52.0%+1.6pp	49.5%+1.3pp	N/A	51.4%+1.8pp	50.3%+1.7pp	48.2%+1.9pp	50.1%-4.1pp	49.6%+1.5pp
Operating Margin	-5.6%-16.5pp	16.4%+3.0pp	N/A	19.7%+20.9pp	10.9%+11.0pp	13.3%+19.1pp	-0.7%-17.6pp	-1.2%-10.1pp
Net Margin	-13.9%-20.7pp	9.3%+3.8pp	N/A	9.7%+19.8pp	6.8%+27.1pp	5.5%+9.1pp	-5.1%-15.5pp	-10.1%-11.9pp
Return on Equity	-7.4%-11.6pp	4.5%+1.1pp	N/A	6.0%+13.2pp	4.1%+17.4pp	3.4%+5.3pp	-4.0%-10.2pp	-7.2%-8.2pp
Return on Assets	-1.5%-2.2pp	0.9%+0.4pp	N/A	1.1%+2.1pp	0.7%+2.8pp	0.6%+0.9pp	-0.5%-1.6pp	-1.1%-1.2pp
Current Ratio	0.88-0.2x	1.010.0x	1.04+0.1x	1.11+0.2x	1.06+0.2x	1.03+0.1x	0.980.0x	0.89-0.1x
Debt-to-Equity	4.14-0.7x	3.87-1.3x	4.15-2.1x	4.50-1.3x	4.88-0.6x	5.13+0.3x	6.25+1.5x	5.83+0.8x
Asset Turnover	0.100.0x	0.100.0x	0.04-0.1x	0.110.0x	0.100.0x	0.100.0x	0.110.0x	0.100.0x
FCF Margin	7.4%+4.3pp	-5.2%+0.7pp	67.7%+57.2pp	5.2%-7.4pp	3.1%+3.0pp	-6.0%+0.5pp	10.5%-13.3pp	12.6%+16.3pp

Where TEVA PHARM INDUS LTD Ranks

Frequently Asked Questions

What is TEVA PHARM INDUS LTD's annual revenue?

TEVA PHARM INDUS LTD (TEVJF) reported $17.3B in total revenue for fiscal year 2025. This represents a 4.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is TEVA PHARM INDUS LTD's revenue growing?

TEVA PHARM INDUS LTD (TEVJF) revenue grew by 4.3% year-over-year, from $16.5B to $17.3B in fiscal year 2025.

Is TEVA PHARM INDUS LTD profitable?

Yes, TEVA PHARM INDUS LTD (TEVJF) reported a net income of $1.4B in fiscal year 2025, with a net profit margin of 8.2%.

What is TEVA PHARM INDUS LTD's EBITDA?

TEVA PHARM INDUS LTD (TEVJF) had EBITDA of $3.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is TEVA PHARM INDUS LTD's gross margin?

TEVA PHARM INDUS LTD (TEVJF) had a gross margin of 51.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is TEVA PHARM INDUS LTD's operating margin?

TEVA PHARM INDUS LTD (TEVJF) had an operating margin of 12.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is TEVA PHARM INDUS LTD's net profit margin?

TEVA PHARM INDUS LTD (TEVJF) had a net profit margin of 8.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is TEVA PHARM INDUS LTD's return on equity (ROE)?

TEVA PHARM INDUS LTD (TEVJF) has a return on equity of 17.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is TEVA PHARM INDUS LTD's free cash flow?

TEVA PHARM INDUS LTD (TEVJF) generated $1.1B in free cash flow during fiscal year 2025. This represents a 53.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is TEVA PHARM INDUS LTD's operating cash flow?

TEVA PHARM INDUS LTD (TEVJF) generated $1.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are TEVA PHARM INDUS LTD's total assets?

TEVA PHARM INDUS LTD (TEVJF) had $40.7B in total assets as of fiscal year 2025, including both current and long-term assets.

What are TEVA PHARM INDUS LTD's capital expenditures?

TEVA PHARM INDUS LTD (TEVJF) invested $501.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does TEVA PHARM INDUS LTD spend on research and development?

TEVA PHARM INDUS LTD (TEVJF) invested $1.0B in research and development during fiscal year 2025.

How many shares does TEVA PHARM INDUS LTD have outstanding?

TEVA PHARM INDUS LTD (TEVJF) had 1.15B shares outstanding as of fiscal year 2025.

What is TEVA PHARM INDUS LTD's current ratio?

TEVA PHARM INDUS LTD (TEVJF) had a current ratio of 1.04 as of fiscal year 2025, which is considered adequate.

What is TEVA PHARM INDUS LTD's debt-to-equity ratio?

TEVA PHARM INDUS LTD (TEVJF) had a debt-to-equity ratio of 4.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is TEVA PHARM INDUS LTD's return on assets (ROA)?

TEVA PHARM INDUS LTD (TEVJF) had a return on assets of 3.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is TEVA PHARM INDUS LTD's Altman Z-Score?

TEVA PHARM INDUS LTD (TEVJF) has an Altman Z-Score of 0.74, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is TEVA PHARM INDUS LTD's Piotroski F-Score?

TEVA PHARM INDUS LTD (TEVJF) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are TEVA PHARM INDUS LTD's earnings high quality?

TEVA PHARM INDUS LTD (TEVJF) has an earnings quality ratio of 1.17x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can TEVA PHARM INDUS LTD cover its interest payments?

TEVA PHARM INDUS LTD (TEVJF) has an interest coverage ratio of 2.35x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.